Using induced pluripotent stem cells for drug discovery in arrhythmias.

Arrythmia cardiomyocytes disease modeling drug development human induced pluripotent stem cells

Journal

Expert opinion on drug discovery
ISSN: 1746-045X
Titre abrégé: Expert Opin Drug Discov
Pays: England
ID NLM: 101295755

Informations de publication

Date de publication:
02 Jun 2024
Historique:
medline: 3 6 2024
pubmed: 3 6 2024
entrez: 3 6 2024
Statut: aheadofprint

Résumé

Arrhythmias are disturbances in the normal rhythm of the heart and account for significant cardiovascular morbidity and mortality worldwide. Historically, preclinical research has been anchored in animal models, though physiological differences between these models and humans have limited their clinical translation. The discovery of human induced pluripotent stem cells (iPSC) and subsequent differentiation into cardiomyocyte has led to the development of new The authors describe the latest two-dimensional Human iPSC-derived cardiomyocytes models have significant potential to augment disease modeling, drug discovery, and toxicity studies in preclinical development. While there is initial success with modeling arrhythmias, the field is still in its nascency and requires advances in maturation, cellular diversity, and readouts to emulate arrhythmias more accurately.

Identifiants

pubmed: 38825838
doi: 10.1080/17460441.2024.2360420
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1-14

Auteurs

Diogo Teles (D)

Department of Biomedical Engineering, Columbia University, New York, NY, USA.

Barry M Fine (BM)

Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA.

Classifications MeSH